Shionogi Shares Surge as Cost Discipline Drives Profits Higher Than Sales
Japanese pharmaceutical firm Shionogi & Co. reported robust nine-month results, with net income growth significantly outpacing revenue increases. The performance highlights the company's effective cost management and strategic portfolio shifts, though analysts caution that future growth hinges on key pipeline products and regulatory approvals.